8 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
TB: • HIV • Recent ... • HIV: 2/3 pulmonary ... characteristic features Clinical ... Tuberculin skin test ... #Diagnosis #Management
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
TB: • HIV • Recent ... • HIV: 2/3 pulmonary ... characteristic features Clinical ... Tuberculin skin test ... #Diagnosis #Management
Tuberculosis Testing

LATENT TB
• LTBI is diagnosed when an asymptomatic patient has a positive TST or IGRA
Testing LATENT TB ... • LTBI is diagnosed ... result with no clinical ... used to exclude pulmonary ... #Workup #TB #Latent
Pott's Disease in Tuberculosis - Diagnosis and Management Summary
Epidemiology:
 - Typically from TB endemic areas
 -
extrapulmonary cases Clinical ... signs/symptoms of active ... pulmonary TB PE ... for concomitant pulmonary ... #Diagnosis #Management
Cryptogenic Organizing Pneumonia (COP)

Cryptogenic Organizing Pneumonia Overview:
 • Idiopathic form of organizing pneumonia
 • formerly BOOP
Organizing Pneumonia - Clinical ... legionella/strep, HIV ... • CTD workup: ... #ILD #diagnosis ... #management
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
(+) screening test ... no evidence of active ... and molecular diagnostic ... persons with clinical ... Prevention #Treatment #management
Immune Reconstitution Inflammatory Syndrome - Overview of IRIS

What Is IRIS?
	• A state of hyperinflammatory response that
noncompliance • Clinical ... initiation Clinical ... , pulmonary infiltrates ... • Persistently active ... #Management
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
salivary ducts Clinical ... , INC risk PE, Pulmonary ... MALT Lymphoma • Lung ... muscarinic agonists • Active ... #Management